Brian Rini
机构: Vanderbilt University Medical Center
每年引用次数
引用次数
引用: 82,216
H-指数: 127
I10-指数 : 564
出版物: 1,236
Renal Cell Carcinoma
Brian I Rini , Bernard Escudier , Steven C Campbell
1,935
2009
Targeted therapy for metastatic renal cell carcinoma: a home run or a work in progress?
Brian I Rini , Ronald M. Bukowski
Oncology 22 ( 4) 388 -396
13
2008
Biomarkers: hypertension following anti-angiogenesis therapy.
Brian I Rini
Clinical advances in hematology & oncology 8 ( 6) 415 -416
11
2010
Prognostic factors in renal carcinoma.
N. J. Vogelzang , Brian I Rini
Seminars in Oncology 27 ( 2) 213 -220
39
2000
Highlights in renal cell carcinoma from the 2012 American Society of Clinical Oncology Annual Meeting.
Brian I Rini
Clinical advances in hematology & oncology 10 1 -24
2012
The Wolchok/Motzer article reviewed
Brian I Rini , Nicholas J. Vogelzang
Oncology 14 ( 1)
2000
Current and emerging first-line systemic therapies in clear cell renal cell carcinoma.
Brian I Rini
Clinical advances in hematology & oncology 16 ( 2) 115 -117
2018
Abstract PS7-01: Characteristics and outcomes of SARS-CoV-2 infection in patients with invasive breast cancer (BC) from the COVID-19 and cancer consortium (CCC19) cohort study
Nicole M Kuderer , Toni K Choueiri , Brian I Rini , Petros Grivas
Cancer Research 81 ( 4) 2
2021
Clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1/PD-L1 in Renal Cell Carcinoma
Brian I Rini , W Kimryn Rathmell , Kimberly B Dahlman , Eric Jonasch
Cancers 13 ( 6) 1475
2021
Are immune checkpoint combination therapies for intermediate and poor risk renal cell carcinoma better than immune checkpoint inhibitors combined with kinase inhibitors
Brian I Rini , David F McDermott , Michael B Atkins
Lancet Oncology 22 ( 5) 593 -594
2021
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
Brian I Rini , Thomas Powles , Michael B Atkins , Bernard Escudier
The Lancet 393 ( 10189) 2404 -2415
724
2019
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
Brian I Rini , Bernard Escudier , Piotr Tomczak , Andrey Kaprin
The Lancet 378 ( 9807) 1931 -1939
1,336
2011
Renal cell carcinoma.
W Kimryn Rathmell , Caroline A Martz , Brian I Rini
Current Opinion in Oncology 14 ( 3) 261 -267
247
2007
A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer.
Daniel Y. C. Heng , Kim N Chi , Nevin Murray , Tao Jin
Cancer 115 ( 4) 776 -783
56
2009
On-treatment biomarkers in metastatic renal cell carcinoma: towards individualization of prognosis?
Frede Donskov , Daniel Y C Heng , Brian I Rini
Expert Review of Anticancer Therapy 17 ( 2) 97 -99
2
2017
Targeted therapy in renal cell carcinoma.
Bhanu K Vakkalanka , Brian I Rini
Current Opinion in Urology 18 ( 5) 481 -487
13
2008
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
Toni K Choueiri , Bernard Escudier , Thomas Powles , Nizar M Tannir
The Lancet Oncology 17 ( 7) 917 -927
490
2016
Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial
Brian I Rini , Tanya B Dorff , Paul Elson , Cristina Suarez Rodriguez
The Lancet Oncology 17 ( 9) 1317 -1324
96
2016
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial
Brian I Rini , Arnulf Stenzl , Romauld Zdrojowy , Mikhail Kogan
The Lancet Oncology 17 ( 11) 1599 -1611
187
2016
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial
Toni K Choueiri , James Larkin , Mototsugu Oya , Fiona Thistlethwaite
Lancet Oncology 19 ( 4) 451 -460
241
2018